Share
    NEW SEARCH RETURN TO SEARCH RESULTS
Number: 201308046 Principal Investigator: Adkins, Douglas
Title: A Randomised, Double-Blind, Placebo-Controlled, Multi-Centre Phase III Study to Assess the Efficacy and Safety of Vandetanib (CAPRELSA™) 300 mg in Patients with Papillary or Poorly Differentiated Thyroid Cancer That Is Either Locally Advanced or Metastatic Who Are Refractory or Unsuitable for Radioiodine (RAI) Therapy
Phase: III Disease Site: Thyroid
Participating Site(s):
 
Main Campus
Map and Directions
South County
Map and Directions
St. Peters
Map and Directions
West County
Map and Directions
 
Contact: 800-600-3606 or info@ccadmin.wustl.edu

Description:
The purpose of this study is to investigate if vandetanib can help keep thyroid cancer from growing, or progressing. This study will also explore which patients respond best to
vandetanib, how vandetanib works, and how vandetanib is tolerated in patients with thyroid cancer. This study will also measure the amount of vandetanib in the blood.
 
More Information:
ClinicalTrials.Gov Link
Internal Protocol Documents (requires Siteman administrative database password)